GlassScriptPhysician profile
Mario A Quintanilla
NPI 1871552729
$1,060.70
in general payments reported to CMS, 2019-2025
13 companies · $96.79 in 2025
The $96.79 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.67 · 2022: $140 · 2023: $365 · 2024: $443 · 2025: $96.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $200.28 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $186.63 | 2023-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $143.56 | 2023-2024 | Austedo Xr, Austedo |
| Tris Pharma INC | $108.18 | 2023-2024 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $88.85 | 2022 | |
| Alkermes, INC. | $81.72 | 2022-2023 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $62.28 | 2024-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.07 | 2022-2025 | Caplyta |
| Lundbeck LLC | $45.38 | 2024 | Rexulti |
| Brainsway USA INC | $35.97 | 2024 | Brainsway Deep Tms System |
| Neuronetics, INC. | $23.11 | 2023 | Neurostar Tms Therapy System |
| Validus Pharmaceuticals LLC | $22.00 | 2023 | Equetro |
| Neurocrine Biosciences, INC. | $15.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Quintanilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.